QBFM
ECYT

QS Batterymarch Financial Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

QS Batterymarch Financial Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$597K Sell
98,180
-14,127
-13% -$96.5K 0.02% 582
2014
Q2 		$741K Hold
112,307
– – 0.02% 563
2014
Q1 		$2.67M Sell
112,307
-7,000
-6% -$101K 0.06% 437
2013
Q4 		$1.27M Sell
119,307
-950
-0.8% -$10.5K 0.03% 584
2013
Q3 		$1.6M Sell
120,257
-64,043
-35% -$1.01M 0.03% 540
2013
Q2 		$2.42M Buy
+184,300
New +$2.49M 0.05% 479

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

QS Batterymarch Financial Management's ECYT Position: Q3 2014 in Review

QS Batterymarch Financial Management reduced its Endocyte, Inc. Common Stock (ECYT) stake by 13% in Q3 2014, selling an estimated $96.5K and leaving 98,180 shares worth $597K. The position accounts for 0.02% of the portfolio, ranked #582.

QS Batterymarch Financial Management first reported a position in ECYT in Q2 2013 and has held it in 6 quarters since. The position peaked at $2.67M in Q1 2014. 101 funds tracked by Wall St. Rank hold ECYT as of Q3 2014.

  • QS Batterymarch Financial Management held 98,180 shares of Endocyte, Inc. Common Stock worth $597K as of Q3 2014.
  • QS Batterymarch Financial Management sold 14,127 Endocyte, Inc. Common Stock shares in Q3 2014, an estimated $96.5K.
  • Endocyte, Inc. Common Stock made up 0.02% of QS Batterymarch Financial Management's portfolio in Q3 2014, its #582 holding.
  • QS Batterymarch Financial Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and has held it in 6 quarters since.
  • QS Batterymarch Financial Management's Endocyte, Inc. Common Stock position peaked at $2.67M in Q1 2014.
  • 101 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2014.

Based on QS Batterymarch Financial Management's 13F filing for Q3 2014, filed 14 Nov 2014.